JP Morgan Maintains Overweight on Progyny, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anne Samuel maintains an Overweight rating on Progyny (NASDAQ:PGNY) but lowers the price target from $31 to $22.
September 19, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan's analyst Anne Samuel maintains an Overweight rating on Progyny but reduces the price target from $31 to $22, indicating a more cautious outlook.
The reduction in the price target from $31 to $22 suggests a more cautious outlook on Progyny's future performance, which could lead to a short-term negative impact on the stock price. However, the maintained Overweight rating indicates continued confidence in the company's long-term potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100